Last reviewed · How we verify
Anti-COVID-19 human immunoglobulin
Anti-COVID-19 human immunoglobulin works by providing pre-formed antibodies to neutralize the SARS-CoV-2 virus.
Anti-COVID-19 human immunoglobulin works by providing pre-formed antibodies to neutralize the SARS-CoV-2 virus. Used for Prevention of COVID-19 in individuals at high risk of severe disease.
At a glance
| Generic name | Anti-COVID-19 human immunoglobulin |
|---|---|
| Sponsor | Lifefactors Zona Franca, SAS |
| Drug class | Monoclonal antibody |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
This monoclonal antibody therapy is designed to provide immediate protection against COVID-19 by targeting the spike protein of the virus, thereby preventing it from entering host cells. The human immunoglobulin is derived from donors who have been immunized against COVID-19, providing a pool of pre-formed antibodies that can neutralize the virus.
Approved indications
- Prevention of COVID-19 in individuals at high risk of severe disease
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 (PHASE1)
- Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 (NA)
- A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults (PHASE1)
- A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults (PHASE1)
- Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19 (PHASE1)
- A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects (PHASE1)
- Tocilizumab for Patients With Cancer and COVID-19 Disease (PHASE2)
- Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-COVID-19 human immunoglobulin CI brief — competitive landscape report
- Anti-COVID-19 human immunoglobulin updates RSS · CI watch RSS
- Lifefactors Zona Franca, SAS portfolio CI